Jazz Pharmaceuticals to buy Chimerix for $935 million
05/03/2025 12:06
March 5 (Reuters) - Jazz Pharmaceuticals JAZZ.O will acquire biotech firm Chimerix CMRX.O for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday. (Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032